drugset
drugset / Trial / NCT00887354

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

NCT00887354 ↗

Phase 4 Completed 224 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate whether teriparatide is superior to the active comparator in the change from baseline of lumbar spine BMD (bone mineral density) in men and postmenopausal women with low bone mass and a recent pertrochanteric hip fracture.

Timeline

Start
2009-04
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Risedronate Small molecule 35 mg Oral
Subject Teriparatide Protein / enzyme biologic 20 ug Subcutaneous

Indications

osteoporosis